1 week ago
Tyra Biosciences (TYRA) Shares Plunge 22% as Bladder Cancer Drug Trial Falls Short
Tyra Biosciences (TYRA) stock plunged 22% after its bladder cancer drug dabogratinib achieved a 64% response rate, missing the 70% analyst benchmark.
The post Tyra Biosciences (TYRA) Shares Plunge 22% as Bladder Cancer Drug Trial Falls Short appeared first on Blockonomi.
Source: Blockonomi →Related News
- 9 hours ago
Ionis Pharmaceuticals, Inc. (IONS) Stock: Surges as Phase 3 ALS Trial Delivers P...
- 10 hours ago
PayPal Holdings, Inc. (PYPL) Stock: Muse Partnership Opens New AI Commerce Route
- 10 hours ago
Amazon.com, Inc. (AMZN) Stock: Amazon Blocks Meta’s Muse Shopping Agent
- 11 hours ago
SpaceX (SPCX) Stock: Advances as Merger Speculation Drives Attention
- 12 hours ago
NVIDIA (NVDA) Stock: Gains as Apple Challenges Cloud AI With New Macs